CG Bio Showcases UBE Tools at Melbourne Congress
The regenerative medicine company exhibited surgical instruments, imaging systems and spinal implants at the 2026 World UBE Society Australia Annual Congress.
Updated on Nov. 6, 2026 in Biotech
CG Bio, a global regenerative medicine company, served as a gold sponsor of the 2026 World UBE Society Australia Annual Congress in Melbourne. The company operated an exhibition booth at the RACV City Club from October 23 to 25, displaying its UBE surgical instrument set and other spinal and bone products.
Why it matters
The participation reflects CG Bio's effort to position its products within the operating room rather than selling individual items. The company is also using its existing bone substitute business in New Zealand as a base for discussing additional product introductions with distributors in Australia and New Zealand.
The announcement is a company-issued sponsorship and exhibition notice rather than independent data. CG Bio currently supplies Novosis in New Zealand via LifeHealthcare, but no sales figures or market-share numbers were disclosed.
The players
CG Bio
CG Bio is a global regenerative medicine company that markets spinal implants, bone graft materials and surgical instruments across international markets.
LifeHealthcare
LifeHealthcare is an Australian medical device distributor that currently carries CG Bio's Novosis bone substitute into the New Zealand market.
The details
CG Bio displayed Multifocus, a UBE-dedicated instrument set from its subsidiary CG MedTech, alongside the ELICA 4K imaging system from Solendos. The booth also featured the Colonnade pedicle screw system, the Xcender height-expandable cage, and the Novosis, Bongener and Allomix bone materials.
Timeline
October 23 to 25, 2026: CG Bio exhibition booth operated at the RACV City Club in Melbourne.
Biotech Landscape
CG Bio's push centers on unilateral biportal endoscopy, a minimally invasive spinal technique that uses two small portals and an endoscope rather than a single large incision. The company's expansion into Australia and New Zealand follows its prior positioning of spinal implant and bone graft products in the global spine surgery market.
For surgeons and hospitals in Australia and New Zealand, expanded access to UBE instruments and spinal implants could widen the range of equipment available for minimally invasive procedures. Patients may see such techniques offered as local distributors add products, though timing depends on each country's licensing approvals.
The takeaway
Companies in spinal surgery are increasingly tying new instrument launches to specific minimally invasive techniques like UBE. Clinicians evaluating these tools should watch for regulatory approvals in their own country before assuming availability.
Further reading
Explore more in Biotech coverage of medical device and regenerative medicine developments.
Source note: This article includes information reported by Business Korea.
